Aradigm Corporation (Nasdaq:ARDM) (“Aradigm" or the “Company”) today announced that President and CEO, Igor Gonda, will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016, at 1:00 p.m. ET. The event will be held at the Sofitel New York in New York, New York.
Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company's Web site for 60 days.
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm is currently in Phase 3 development of Pulmaquin® (an investigational proprietary formulation of ciprofloxacin for inhalation) for the treatment of non-cystic fibrosis bronchiectasis. Aradigm’s inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
More information about Aradigm can be found at www.aradigm.com.
Aradigm, Pulmaquin and the Aradigm Logo are registered trademarks of Aradigm Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005539/en/Business Wire
Last updated on: 20/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.